The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Characteristics and predictors of chronic immune-related adverse events (irAEs) following anti-PD-1 (PD1) treatment for melanoma.
 
Roma Kankaria
No Relationships to Disclose
 
Andrea Boutros
No Relationships to Disclose
 
Marlies Pinzon
No Relationships to Disclose
 
Reilly Fankhauser
Stock and Other Ownership Interests - Lilly; Novo Nordisk
 
Christian Agbisit
No Relationships to Disclose
 
Alissa Kalyan
No Relationships to Disclose
 
Aleigha Lawless
No Relationships to Disclose
 
Georgina Long
Honoraria - BMS; Pierre Fabre
Consulting or Advisory Role - Agenus; Amgen; Array BioPharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Evaxion Biotech; GI Innovation Inc; Hexal; Highlight Therapeutics; Immunocore Ireland Limited; Innovent Biologics; IO Biotech; Merck Sharp & Dohme; Novartis; OncoSec; PHMR; Pierre Fabre; Regeneron; Scancell LImited; Skyline Diagnostics
 
Ryan Sullivan
Consulting or Advisory Role - BridGene Biosciences; Bristol-Myers Squibb; Marengo Therapeutics; Merck; Novartis; Pfizer; Replimune
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BeiGene (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Georgimmune (Inst); Lilly (Inst); Marengo Therapeutics (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Rubius Therapeutics (Inst); Sanofi (Inst); Strategia (Inst); Strategia (Inst); Synthekine (Inst); Viralytics (Inst)
 
Janice Mehnert
Stock and Other Ownership Interests - Pfizer
Honoraria - HMP; Medscape
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Sanofi/Regeneron; Seagen
Research Funding - Amgen (Inst); AstraZeneca (Inst); bristol myers squibb (Inst); Deciphera (Inst); GV20 Therapeutics; Incyte (Inst); Kinnate Biopharma (Inst); macrogenics (Inst); macrogenics (Inst); Merck (Inst); Novartis (Inst); Regeneron (Inst)
 
Suthee Rapisuwon
Stock and Other Ownership Interests - Cardiff Oncology; Geron
Honoraria - General Dynamics Information Technology (GDIT)
Consulting or Advisory Role - Castle Biosciences; Replimune
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst); Xilio Therapeutics (Inst)
 
Justin Balko
Stock and Other Ownership Interests - Beam Therapeutics; BioNano Genomics; crispr therapeutics
Consulting or Advisory Role - AstraZeneca; Lilly; Malinkrodt; Pfizer
Research Funding - Genentech/Roche; Incyte
Patents, Royalties, Other Intellectual Property - FCRL6 as an immunotherapy target; Patent on use of HLA-DR/MHC expression to predict response to immunotherapies
Other Relationship - NanoString Technologies
 
Matteo Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; IDEAYA Biosciences; Innovent Biologics; Medison; Medison; Merck Serono; Moderna Therapeutics; MSD; Nektar; Novartis; OncoSec; Pierre Fabre; QBiotics; Regeneron; Roche; Sanofi
 
Alexander Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; QBiotics; Roche
 
Douglas Johnson
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Merck; Novartis; Pfizer; Targovax; The Jackson Laboratory
Research Funding - Bristol-Myers Squibb; Incyte
Patents, Royalties, Other Intellectual Property - Abatacept for the use of immune related adverse events.; Intellectual property and patents pending surrounding use of MHC-II and response to immune therapy